Molecular determinants of outcomes in meningiomas

John Lynes; John Lynes; Gabriel Flores-Milan; Gabriel Flores-Milan; Sebastian Rubino; Sebastian Rubino; John Arrington; Robert Macaulay; James K. C. Liu; James K. C. Liu; Andre Beer-Furlan; Andre Beer-Furlan; Nam D. Tran; Nam D. Tran; Michael A. Vogelbaum; Michael A. Vogelbaum; Arnold B. Etame; Arnold B. Etame

doi:10.3389/fonc.2022.962702

Frontiers in Oncology (Aug 2022)

Molecular determinants of outcomes in meningiomas

John Lynes,
John Lynes,
Gabriel Flores-Milan,
Gabriel Flores-Milan,
Sebastian Rubino,
Sebastian Rubino,
John Arrington,
Robert Macaulay,
James K. C. Liu,
James K. C. Liu,
Andre Beer-Furlan,
Andre Beer-Furlan,
Nam D. Tran,
Nam D. Tran,
Michael A. Vogelbaum,
Michael A. Vogelbaum,
Arnold B. Etame,
Arnold B. Etame

Affiliations

John Lynes: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
John Lynes: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Gabriel Flores-Milan: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Gabriel Flores-Milan: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Sebastian Rubino: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Sebastian Rubino: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
John Arrington: Department of Radiology, Moffitt Cancer Center, Tampa, FL, United States
Robert Macaulay: Department of Pathology, Moffitt Cancer Center, Tampa, FL, United States
James K. C. Liu: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
James K. C. Liu: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Andre Beer-Furlan: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Andre Beer-Furlan: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Nam D. Tran: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Nam D. Tran: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Michael A. Vogelbaum: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Michael A. Vogelbaum: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States
Arnold B. Etame: Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States
Arnold B. Etame: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States

DOI: https://doi.org/10.3389/fonc.2022.962702
Journal volume & issue: Vol. 12

Abstract

Read online

Meningiomas are the most common intracranial primary tumor in adults. Surgery is the predominant therapeutic modality for symptomatic meningiomas. Although the majority of meningiomas are benign, there exists a subset of meningiomas that are clinically aggressive. Recent advances in genetics and epigenetics have uncovered molecular alterations that drive tumor meningioma biology with prognostic and therapeutic implications. In this review, we will discuss the advances on molecular determinants of therapeutic response in meningiomas to date and discuss findings of targeted therapies in meningiomas.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords